- New
-
Topics
- All Categories
- Metaphysics and Epistemology
- Value Theory
- Science, Logic, and Mathematics
- Science, Logic, and Mathematics
- Logic and Philosophy of Logic
- Philosophy of Biology
- Philosophy of Cognitive Science
- Philosophy of Computing and Information
- Philosophy of Mathematics
- Philosophy of Physical Science
- Philosophy of Social Science
- Philosophy of Probability
- General Philosophy of Science
- Philosophy of Science, Misc
- History of Western Philosophy
- Philosophical Traditions
- Philosophy, Misc
- Other Academic Areas
- Journals
- Submit material
- More
The Accelerated Approval of Aducanumab Invites a Rethink of the Current Model of Drug Development for Alzheimer's Disease
American Journal of Bioethics Neuroscience 14 (3):332-335 (2023)
Abstract
It is a tale of two Pfizers. In 2018 they abandoned research into the leading cause of dementia, Alzheimer’s Disease (AD) (Hawkes 2018). In 2021, they developed the first vaccine for Covid-19 to re...My notes
Similar books and articles
Alzheimer's and Aducanumab: Unjust Profits and False Hopes.Leonard M. Fleck - 2021 - Hastings Center Report 51 (4):9-11.
Commentary to ‘Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population’.Maria Eriksdotter - 2021 - Journal of Medical Ethics 47 (9):617-617.
Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population.Erik Gustavsson, Pauline Raaschou, Gerd Lärfars, Lars Sandman & Niklas Juth - 2021 - Journal of Medical Ethics 47 (9):608-614.
The use of evidence of mechanisms in drug approval.Jeffrey Aronson, Adam La Caze, Michael Kelly, Veli-Pekka Parkkinen & Jon Williamson - forthcoming - Journal of Evaluation in Clinical Practice.
How accelerated Golgi trafficking may drive Alzheimer's disease (comment on DOI 10.1002/bies.201400116) .Genevieve Evin - 2015 - Bioessays 37 (3):232-233.
Descartes RV 5-8. 14. 25 diagnosis of Alzheimer's disease 132 Down syndrome 67. 132 early detection of brain pathology in Alzheimer's disease 131-143. [REVIEW]C. Bernard - 1992 - In Y. Christen & P. S. Churchland (eds.), Neurophilosophy and Alzheimer's Disease. Springer Verlag. pp. 80--151.
Research involving subjects with Alzheimer’s disease in Italy: the possible role of family members.Corinna Porteri & Carlo Petrini - 2015 - BMC Medical Ethics 16 (1):12.
Reprioritizing Research Activity for the Post‐Antibiotic Era: Ethical, Legal, and Social Considerations.Spencer Phillips Hey & Aaron S. Kesselheim - 2017 - Hastings Center Report 47 (2):16-20.
Drug Trials, Doctors, and Developing Countries: Toward a Legal Definition of Informed Consent.Adina M. Newman - 1996 - Cambridge Quarterly of Healthcare Ethics 5 (3):387.
The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators.Erik Gustavsson, Pauline Raaschou, Gerd Lärfars, Lars Sandman & Niklas Juth - 2022 - Journal of Medical Ethics 48 (3):193-193.
Stimulating the development of drug treatments to improve cognition in schizophrenia.Micahel F. Green - manuscript
Classification of Alzheimer's Disease Using Convolutional Neural Networks.Lamis F. Samhan, Amjad H. Alfarra & Samy S. Abu-Naser - 2022 - International Journal of Academic Information Systems Research (IJAISR) 6 (3):18-23.
Stakeholders’ Views on Early Diagnosis for Alzheimer’s Disease, Clinical Trial Participation and Amyloid PET Disclosure: A Focus Group Study.Gwendolien Vanderschaeghe, Rik Vandenberghe & Kris Dierickx - 2019 - Journal of Bioethical Inquiry 16 (1):45-59.
Analytics
Added to PP
2022-04-08
Downloads
19 (#750,145)
6 months
9 (#242,802)
2022-04-08
Downloads
19 (#750,145)
6 months
9 (#242,802)
Historical graph of downloads
Citations of this work
An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease.Timothy Daly, Karl Herrup & Alberto J. Espay - 2024 - American Journal of Bioethics Neuroscience 15 (2):80-81.
References found in this work
Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?Holly Fernandez Lynch, Arthur Caplan, Patricia Furlong & Alison Bateman-House - 2021 - American Journal of Bioethics 21 (12):4-19.
On the reconceptualization of Alzheimer’s disease.Maartje Schermer & Edo Richard - 2018 - Bioethics 33 (1):138-145.
Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population.Erik Gustavsson, Pauline Raaschou, Gerd Lärfars, Lars Sandman & Niklas Juth - 2021 - Journal of Medical Ethics 47 (9):608-614.
The ethics of innovation for Alzheimer’s disease: the risk of overstating evidence for metabolic enhancement protocols.Timothy Daly, Ignacio Mastroleo, David Gorski & Stéphane Epelbaum - 2020 - Theoretical Medicine and Bioethics 41 (5):223-237.
Alzheimer's and Aducanumab: Unjust Profits and False Hopes.Leonard M. Fleck - 2021 - Hastings Center Report 51 (4):9-11.
PhilPapers logo by Andrea Andrews and Meghan Driscoll.
This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications). Use of this site is subject to terms & conditions.
All rights reserved by The PhilPapers Foundation
Server: philpapers-web-6d9b7f7c4c-v4fj8 uwo